Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatmen... (interferon-alpha. Published data indicat...)

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus

Date:8/12/2008

interferon-alpha. Published data indicate that levels of interferon-alpha are elevated in many patients with active SLE and other autoimmune disorders, and may be associated with disease activity. Preclinical data from animal models suggest that MEDI-545 may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

In November 2004, MedImmune entered into a collaboration with Medarex to focus on two specific antibodies, one of which was MDX-1103 (now known as MEDI-545). Under the terms of the agreement, MedImmune is responsible for all ongoing clinical development activities. Prior to the beginning of pivotal studies, Medarex may elect to co-develop the products in return for the opportunity to co-promote and to receive a share of the commercial profits in the United States. In all other cases, Medarex will be entitled to receive milestone payments and royalties.

About Lupus

Approximately 350,000 individuals in the United States are affected with lupus, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat arthritis patients. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) tec
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain

Post Your Comments:

(Date:5/22/2013)... 22, 2013 Upsher-Smith Laboratories, Inc. ... its global Phase III clinical trial for ... for the management of epilepsy in adults, ... is specifically engineered to provide convenient once-daily ... levels observed with currently available treatment options. ...

(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter. The Facebook homepage ... Says CEO Bruce J. ...

(Date:5/22/2013)... TORONTO , May 22, 2013 Generex ... three presentations demonstrating the superiority of the AE37 breast ... Express, Inc. ( www.antigenexpress.com ). The presentations will be ... of Clinical Oncology (ASCO) to be held in ... 4, 2013. The presentation entitled " Booster ...

Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3 Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4 Medifirst Solutions, Inc. Announces Update To Shareholders 2 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4

[0] Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures [0] Medifirst Solutions, Inc. Announces Update To Shareholders [0] Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine

... N. J. ,Oct. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical ... developer, manufacturer and marketer of medical devices worldwide, today ... hand-held M series ultrasound platforms at the American Society ... October 14-18, 2011. The M7 ...

... MAHWAH, N.J., Oct. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray ... a leading developer, manufacturer and marketer of medical ... A3 anesthesia system, an expansion of its A ... that complements Mindray,s broad range of ultrasound and ...

Cached Medicine Technology:Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA 2 Mindray Announces Expansion of its A Series Anesthesia Portfolio 2

Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA Mindray Announces Expansion of its A Series Anesthesia Portfolio

(Date:5/22/2013)... A new study shows there is a gender ... American young children one that does not appear ... United States, girls had higher levels of self-regulation than ... their behavior and impulses, follow directions, and persist on ... and college completion, in past studies by Oregon State ...

(Date:5/22/2013)... New York, New York (PRWEB) May 22, 2013 ... a metal-on-metal version of the DePuy Pinnacle Hip Replacement ... underway in Texas Federal Court, Bernstein Liebhard LLP reports. ... Court has directed DePuy Orthopaedics to produce monitoring reports ... government into the company’s medical device marketing practices. ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Twenty student-led ... next year participating in an intensive startup accelerator designed ... products or services and create local jobs as part ... Each year the Edson initiative offers approximately 20 student ... space, mentorship and training to launch their for-profit, more-than-profit ...

(Date:5/22/2013)... News) -- Over the next two decades, the cost ... to more than double, topping more than $180 billion ... factor driving the increase: an aging population. The report, ... Stroke Association, was published May 22 in the journal ... health care system," Dr. Bruce Ovbiagele, chairman of the ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Phelps Memorial ... the Westchester Lung Nodule Center for individuals who ... lung cancer care. Lung cancer is the deadliest form of ... people in the U.S. die from lung cancer than from ... all cancers, early detection increases survival rates. It is ...

[0] 'Boys will be boys' in US, but not in Asia [0] DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort [0] Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report [0] Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care

... PLAINS, N.Y. , Jan. 14 APS Healthcare ... first two winners of its Outcomes Informed Care (OIC) Award, Pepper ... Mona Saylor , MSW, LISW, of Columbia, S.C. ... contribution to the APS OIC initiative, designed to increase the effectiveness ...

... But tumor-type mixups don,t necessarily negate findings, experts say ... rely on specific tumor cell lines when developing new ... to be, a Dutch team reports. , Their study ... lines widely used for worldwide research were actually cell ...

... , UPLAND, Calif. , ... has launched its first line of all natural food bars ... net profits after taxes are donated to Marathon of Miracles, ... www.marathonofmiracles.org . , MOM all natural bars come in two ...

... , Medifast revenue has had over 40% compound year -over-year ... MILLS, Md. , Jan. 14 Medifast, Inc. (NYSE: ... attacks on its stock in a case of outright, deliberate, and possibly ... Minkow , a convicted felon, and his Fraud Discovery Institute (FDI) posted ...

... ... Bedroom , ... NY (Vocus) January 14, 2010 -- Austin Air Systems, America’s leading indoor air ... (NSF) to launch a new National Sleep Foundation-branded air purification system specifically designed ...

... ... the H1N1 shot , ... MA (Vocus) January 14, 2010 -- With flu experts predicting another wave of H1N1 flu, ... vaccination is now readily available and covered by your BCBSMA health plan. BCBSMA members are ...

Cached Medicine News:Health News:APS Healthcare Issues First Award to South Carolina Providers Using Data to Increase Effectiveness of Mental Health Treatment 2 Health News:APS Healthcare Issues First Award to South Carolina Providers Using Data to Increase Effectiveness of Mental Health Treatment 3 Health News:Incorrect Cell Lines Used for Worldwide Cancer Research 2 Health News:Incorrect Cell Lines Used for Worldwide Cancer Research 3 Health News:Marathon of Miracles(TM) All Natural Food Bars and Nuts Begin the Race Towards Good Health 2 Health News:Medifast, Inc. Complaints Against FDI Pending With the United States Department of Justice, the United States Securities and Exchange Commission, the Maryland Securities Commissioner 2 Health News:Medifast, Inc. Complaints Against FDI Pending With the United States Department of Justice, the United States Securities and Exchange Commission, the Maryland Securities Commissioner 3 Health News:Medifast, Inc. Complaints Against FDI Pending With the United States Department of Justice, the United States Securities and Exchange Commission, the Maryland Securities Commissioner 4 Health News:Medifast, Inc. Complaints Against FDI Pending With the United States Department of Justice, the United States Securities and Exchange Commission, the Maryland Securities Commissioner 5 Health News:Austin Air Systems Partners With National Sleep Foundation 2 Health News:Austin Air Systems Partners With National Sleep Foundation 3 Health News:Austin Air Systems Partners With National Sleep Foundation 4 Health News:Blue Cross Blue Shield of Massachusetts Urges Members to Get Their Flu Shot 2

APS Healthcare Issues First Award to South Carolina Providers Using Data to Increase Effectiveness of Mental Health Treatment Incorrect Cell Lines Used for Worldwide Cancer Research Marathon of Miracles(TM) All Natural Food Bars and Nuts Begin the Race Towards Good Health Medifast, Inc. Complaints Against FDI Pending With the United States Department of Justice, the United States Securities and Exchange Commission, the Maryland Securities Commissioner Austin Air Systems Partners With National Sleep Foundation Blue Cross Blue Shield of Massachusetts Urges Members to Get Their Flu Shot

... for laboratories looking for time and cost ... operation in terms of easy reagent cassette ... on-board stability., ,URISYS 2400 is a ... capability for medium to high volume laboratories ...

... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...

Acufex arthroscopic electrodes are insulated for use in all fluids and come in boxes of 10....

... The Assistant Free ... retractors utilizing Velcro® straps. ... of the surgeon's operative ... personnel. Three retractor styles ...

Medicine Products:

URISYS 2400 Small Joint Ball Electrode Electrode Assistant Free™ Knee Retractor System